Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7133046 | 0.88 | LOXL2 (0.44) | CYP3A4CYP2A6MAPTKDM4EMAOB | |
| SCHEMBL19038909 | 0.82 | CYP3A4 (0.57) | CYP3A4CYP2A6MAPTMAOBLOXL2 | |
| SCHEMBL23412378 | 0.80 | MAPT (0.52) | MAPTKDM4ENR3C1HTR1AHTR1D | |
| SCHEMBL23412188 | 0.79 | NCF1 (0.51) | MAPTKDM4EHTR1AHTR1DHTR1B | |
| SCHEMBL96151 | 0.78 | HTR1A (0.45) | MAPTKDM4ENR3C1HTR1AHTR1D | |
| SCHEMBL9601934 | 0.77 | SYK (0.54) | MAPTKDM4ENR3C1HTR1AHTR1D | |
| SCHEMBL27958848 | 0.77 | KDM4E (0.48) | MAPTKDM4ENR3C1HTR1AHTR1D | |
| SCHEMBL23412437 | 0.77 | NCF1 (0.58) | MAPTKDM4EHTR1AHTR1DHTR1B | |
| SCHEMBL94786 | 0.77 | KDM4E (0.48) | CYP3A4MAPTKDM4ENR3C1HTR1A | |
| SCHEMBL28146672 | 0.77 | KDM4E (0.48) | MAPTKDM4ENR3C1HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889546-B2 | Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-20200407319-A1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. | 2020-12-31 | — | — | US | disclosed |
| CN-107848976-B | Alkynyl pyridine prolyl hydroxylase inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3360862-B1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20180305317-A1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-10-25 | — | — | US | disclosed |
| US-9980954-B2 | Quinoline derivatives for inhibiting histone methyltransferases and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-05-29 | — | — | US | disclosed |
| US-20170354650-A1 | QUINOLINE DERIVATIVES FOR INHIBITING HISTONE METHYLTRANSFERASES AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305317-A1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | EGLN3, EGLN2, EPOR | CYP3A4 1066/4885CYP2A6 700/4885MAPT 3982/4885 |
| US-10889546-B2 | Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof | EGLN3, EGLN2, EPOR | CYP3A4 1066/4885CYP2A6 700/4885MAPT 3982/4885 |
| US-20170354650-A1 | QUINOLINE DERIVATIVES FOR INHIBITING HISTONE METHYLTRANSFERASES AND USE THEREOF | NSD1, EHMT1, SETDB1 | CYP3A4 3799/4885CYP2A6 4751/4885MAPT 2983/4885 |
| US-20200407319-A1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | EGLN3, EGLN2, EPOR | CYP3A4 1066/4885CYP2A6 700/4885MAPT 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.